Zhen-Yong Keck

List of Publications by Citations

Source: https://exaly.com/author-pdf/3005986/zhen-yong-keck-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41 1,938 27 42 g-index

42 2,320 7.2 4.28 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
41	Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. <i>PLoS Pathogens</i> , 2012 , 8, e1002653	7.6	160
40	Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. <i>Journal of General Virology</i> , 2008 , 89, 653-659	4.9	121
39	Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. <i>Journal of Virology</i> , 2004 , 78, 9224-32	6.6	121
38	Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. <i>Journal of Virology</i> , 2008 , 82, 6061-6	6.6	99
37	Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. <i>Journal of Virology</i> , 2013 , 87, 37-51	6.6	93
36	Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. <i>Journal of Virology</i> , 2004 , 78, 7257-63	6.6	87
35	Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. <i>Journal of Virology</i> , 2011 , 85, 10451-63	6.6	80
34	Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. <i>Journal of Virology</i> , 2005 , 79, 13199-208	6.6	79
33	Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. <i>Journal of Virology</i> , 2007 , 81, 1043-7	6.6	76
32	Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. <i>Journal of Virology</i> , 2009 , 83, 6149-60	6.6	75
31	Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. <i>Journal of Virology</i> , 2012 , 86, 12923-32	6.6	72
30	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. <i>Cell Reports</i> , 2016 , 15, 1514-1526	10.6	68
29	Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. <i>PLoS Pathogens</i> , 2013 , 9, e1003364	7.6	67
28	Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. <i>Journal of Virology</i> , 2016 , 90, 279-91	6.6	62
27	Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. <i>Gastroenterology</i> , 2012 , 143, 223-233.e9	13.3	60
26	Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E6946-E6954	11.5	56
25	Neutralizing antibody response to hepatitis C virus. <i>Viruses</i> , 2011 , 3, 2127-45	6.2	53

(2015-2015)

24	Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. <i>Journal of Biological Chemistry</i> , 2015 , 290, 10117-25	5.4	48
23	Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. <i>Expert Review of Vaccines</i> , 2016 , 15, 1535-1544	5.2	46
22	Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. <i>PLoS Pathogens</i> , 2014 , 10, e1004297	7.6	46
21	Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. <i>Hepatology</i> , 2016 , 64, 1922-1933	11.2	44
20	A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. <i>Journal of Virology</i> , 2008 , 82, 6067-72	6.6	44
19	Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus. <i>Journal of Virology</i> , 2016 , 90, 3112-22	6.6	41
18	Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells. <i>Journal of Virology</i> , 2019 , 93,	6.6	32
17	Viral evasion and challenges of hepatitis C virus vaccine development. <i>Current Opinion in Virology</i> , 2016 , 20, 55-63	7.5	30
16	Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design. <i>Frontiers in Immunology</i> , 2018 , 9, 1436	8.4	29
15	Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus. <i>Frontiers in Microbiology</i> , 2017 , 8, 2692	5.7	28
14	Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. <i>Journal of Biological Chemistry</i> , 2011 , 286, 44218-44233	5.4	26
13	Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. <i>PLoS Pathogens</i> , 2019 , 15, e1007772	7.6	24
12	A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. <i>Antiviral Research</i> , 2017 , 148, 53-64	10.8	12
11	Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection. <i>Hepatology</i> , 2019 , 70, 1506-1520	11.2	11
10	Isolation of HCV Neutralizing Antibodies by Yeast Display. <i>Methods in Molecular Biology</i> , 2019 , 1911, 395-419	1.4	9
9	An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. <i>Science Advances</i> , 2020 , 6, eabb5642	14.3	9
8	Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization. <i>Journal of Virology</i> , 2020 , 94,	6.6	9
7	An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection. <i>Journal of Virology</i> , 2015 , 89, 4549-61	6.6	7

6	Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	6
5	An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. <i>Gastroenterology</i> , 2021 ,	13.3	2
4	In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. <i>Antiviral Research</i> , 2019 , 162, 136-141	10.8	2
3	Structural perspectives on HCV humoral immune evasion mechanisms. <i>Current Opinion in Virology</i> ,	7.5	2
	2021 , 49, 92-101		
2	Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2112008119	11.5	О